DK0485430T3 - Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis - Google Patents

Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis

Info

Publication number
DK0485430T3
DK0485430T3 DK90911485T DK90911485T DK0485430T3 DK 0485430 T3 DK0485430 T3 DK 0485430T3 DK 90911485 T DK90911485 T DK 90911485T DK 90911485 T DK90911485 T DK 90911485T DK 0485430 T3 DK0485430 T3 DK 0485430T3
Authority
DK
Denmark
Prior art keywords
sepsis
compositions
methods
improving symptoms
antibody molecules
Prior art date
Application number
DK90911485T
Other languages
English (en)
Inventor
Richard Ulevitch
Peter Tobias
Samuel D Wright
John C Mathison
Original Assignee
Scripps Research Inst
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ Rockefeller filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK0485430T3 publication Critical patent/DK0485430T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK90911485T 1989-08-01 1990-07-30 Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis DK0485430T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38781789A 1989-08-01 1989-08-01
PCT/US1990/004250 WO1991001639A1 (en) 1989-08-01 1990-07-30 Methods and compositions for ameliorating the symptoms of sepsis

Publications (1)

Publication Number Publication Date
DK0485430T3 true DK0485430T3 (da) 1999-06-14

Family

ID=23531466

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911485T DK0485430T3 (da) 1989-08-01 1990-07-30 Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis

Country Status (14)

Country Link
US (4) US5730980A (da)
EP (1) EP0485430B1 (da)
JP (1) JP2744130B2 (da)
AT (1) ATE171042T1 (da)
AU (1) AU645515B2 (da)
CA (1) CA2022429C (da)
DE (1) DE69032662T2 (da)
DK (1) DK0485430T3 (da)
ES (1) ES2120948T3 (da)
FI (1) FI920450A0 (da)
GR (1) GR1003164B (da)
IE (1) IE902770A1 (da)
PT (1) PT94869B (da)
WO (1) WO1991001639A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE171042T1 (de) * 1989-08-01 1998-10-15 Scripps Research Inst Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
WO1993019772A1 (en) * 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
AU695124B2 (en) * 1993-05-28 1998-08-06 Scripps Research Institute, The Methods and compositions for inhibiting CD14 mediated cell activation
AU7175694A (en) * 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5891618A (en) 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
DE69534601T2 (de) * 1994-09-16 2006-08-03 The Scripps Research Institute, La Jolla Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
AU691085B2 (en) * 1994-12-30 1998-05-07 Amgen, Inc. Anti-inflammatory CD14 polypeptides
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
WO1996032418A1 (en) * 1995-04-13 1996-10-17 Laboratoires Om S.A. Anti-cd14 antibodies for use in the induction of il-10 secretion
AU6392996A (en) * 1995-06-19 1997-01-15 Sanna M. Goyert A method for inhibiting bacteremia and bacterial dissemination
DK0914144T3 (da) 1996-05-10 2001-04-09 Univ Texas Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
US5945399A (en) * 1996-05-23 1999-08-31 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
DE69917221T2 (de) * 1998-02-07 2005-05-04 Vernalis (Oxford) Ltd., Abington Antibakterielle mittel
ID26730A (id) * 1998-05-27 2001-02-01 Gemma Biotechnology Ltd Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
US6974698B1 (en) * 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
CA2383838A1 (en) 1999-09-17 2001-03-29 Mochida Pharmaceutical Co., Ltd. Method of fractional measurement of soluble cd14 protein
JPWO2002042333A1 (ja) * 2000-11-22 2004-03-25 持田製薬株式会社 Ｃｄ１４／ｔｌｒ結合阻害作用を有する抗ｃｄ１４モノクローナル抗体
WO2002045750A1 (fr) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Medicaments combines
AU2003253621A1 (en) * 2002-06-14 2003-12-31 Centocor, Inc. Modified "s" antibodies
AU2004241069B2 (en) * 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
EP1863844A1 (en) * 2005-02-28 2007-12-12 Centocor, Inc. Heterodimeric protein binding compositions
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
CN103665168A (zh) 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
US20170107294A1 (en) * 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
JP2020517740A (ja) * 2017-04-21 2020-06-18 インプリシット バイオサイエンス プロプライアタリー リミティド 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
ATE171042T1 (de) * 1989-08-01 1998-10-15 Scripps Research Inst Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis

Also Published As

Publication number Publication date
AU6146190A (en) 1991-03-11
PT94869A (pt) 1991-04-18
ATE171042T1 (de) 1998-10-15
US5730980A (en) 1998-03-24
AU645515B2 (en) 1994-01-20
WO1991001639A1 (en) 1991-02-21
IE902770A1 (en) 1991-02-27
PT94869B (pt) 1997-04-30
JPH05501399A (ja) 1993-03-18
EP0485430B1 (en) 1998-09-16
GR1003164B (el) 1999-07-05
CA2022429A1 (en) 1991-02-02
DE69032662D1 (de) 1998-10-22
US6495332B2 (en) 2002-12-17
JP2744130B2 (ja) 1998-04-28
ES2120948T3 (es) 1998-11-16
US20020034509A1 (en) 2002-03-21
EP0485430A4 (en) 1993-03-03
CA2022429C (en) 1998-12-01
FI920450A0 (fi) 1992-01-31
US6045795A (en) 2000-04-04
US6297049B1 (en) 2001-10-02
DE69032662T2 (de) 1999-03-11
GR900100582A (el) 1991-12-30
EP0485430A1 (en) 1992-05-20

Similar Documents

Publication Publication Date Title
DK0485430T3 (da) Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis
ES2169864T3 (es) Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
PT751781E (pt) Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
DE69724451D1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
ES2062355T3 (es) Composicion farmaceutica que comprende loratadina, ibuprofeno y pseudoefedrina.
ATE190623T1 (de) Verwendung von steroiden zur inhibierung von angiogenesis
DK0792162T3 (da) Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
DE69213935T2 (de) Neue heterocyclische carbonsäuren
SE8007074L (sv) Glukagonfragment jemte dess anvendning
DK0643585T3 (da) Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak
DE69123984D1 (de) Verwendung von antikörpern gegen tnf oder die davon abgeleiteten fragmente und xanthinderivate in der kombinationstherapie und zusammensetzungen dazu
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
ES2015349A6 (es) Metodo para producir anticuerpos inmunologicamente reactivos con angiogenina.
RU2003100517A (ru) Новый интерферон для лечения рассеянного склероза
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
FR2303558A1 (fr) Preparation therapeutique pour traiter l'infection sous forme de pneumonie hemorragique du vison et de mastite bovine causees par la pseudomonas aeruginosa
DE69127346D1 (de) Behandlung thrombotischer ereignisse
MA23755A1 (fr) Cyclohexanes-1-ols disubstitues en 4,4 monomeres et composes similaires
ES2085937T3 (es) Desacilacion enzimatica de acil-aminosorbosas y su uso en la fabricacion de 1-desoxinoyirimicina.
NO952608L (no) Derivatiserte kalsitoniner